Recent

% | $
Quotes you view appear here for quick access.

Myrexis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • jacosa jacosa Jun 28, 2011 10:52 AM Flag

    How much more suffering?

    The most likely subjects of news before year-end would be the two pro-drugs. It is possible that there could be a very limited cooperation agreement in the IKke program in that time frame. There is a very small chance that one of the candidates could be sold outright (Management probably wouldn't be interested unless the price was high enough to pay for a study of drug combinations including Azixa against a 'Big 4' cancer). It is possible that the patient with an apparent complete response in the most recently reported Azixa study may be reclassified in the official results (for technical reasons that I don't understand he's considered a non-responder).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MYRX
0.1062-0.0136(-11.35%)Apr 21 11:55 AMEDT